8 results on '"Ávila-Rivera, M. A"'
Search Results
2. Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life
- Author
-
Santos García, Diego, Deus Fonticoba, María Teresa de, Paz González, J. M., Cores Bartolomé, C., Valdés Aymerich, L., Muñoz Enríquez, J. G., Suárez, E., Jesús, S., Aguilar Barberà, Miquel, Pastor, P., Planellas, L. L., Cosgaya, M., García Caldentey, J., Caballol, N., Legarda, I., Hernández-Vara, Jorge, Cabo, I., López Manzanares, L., González Aramburu, I., Ávila-Rivera, M. A, Catalán, M. J., Nogueira, V., Puente, V., García Moreno, José Manuel, Borrué, C., Solano Vila, B., Álvarez Sauco, M., Vela, Lydia, Escalante, S., Cubo, Esther, Carrillo Padilla, F., Martínez Castrillo, J. C., Sánchez Alonso, P., Alonso Losada, M. G., López Ariztegui, N., Gastón, I., Kulisevsky, Jaime, Blázquez Estrada, M., Seijo, M., Rúiz Martínez, J., Valero, C., Kurtis, M., Fàbregues-Boixar i Nebot, Oriol de, González Ardura, J., Ordás, C., López Díaz, L., Mir, P., Martinez-Martin, Pablo, COPPADIS Study Group, None, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Santos García D, Paz González JM, Cores Bartolomé C, Valdés Aymerich L, Muñoz Enríquez JG] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [De Deus Fonticoba T] CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain. [Hernández Vara J, de Fábregues O] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Universidad de Sevilla. Departamento de Medicina, [Santos Garcia, D.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Paz Gonzalez, J. M.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Cores Bartolome, C.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Valdes Aymerich, L.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Munoz Enriquez, J. G.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [De Deus Fonticoba, T.] Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain, [Suarez, E.] Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain, [Jesus, S.] Univ Seville, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Hosp Univ Virgen Rocio,CSIC,Inst Biomed Sevilla, Seville, Spain, [Mir, P.] Univ Seville, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Hosp Univ Virgen Rocio,CSIC,Inst Biomed Sevilla, Seville, Spain, [Jesus, S.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Gonzalez Aramburu, I.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Kulisevsky, J.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Mir, P.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Martinez-Martin, P.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Aguilar, M.] Hosp Univ Mutua Terrassa, Terrassa, Spain, [Pastor, P.] Hosp Univ Mutua Terrassa, Terrassa, Spain, [Planellas, L. L.] Hosp Clin Barcelona, Barcelona, Spain, [Cosgaya, M.] Hosp Clin Barcelona, Barcelona, Spain, [Garcia Caldentey, J.] Ctr Neurol Oms 42, Palma de Mallorca, Spain, [Caballol, N.] Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona, Spain, [Legarda, I.] Hosp Univ Son Espases, Palma de Mallorca, Spain, [Hernandez Vara, J.] Hosp Univ Vall Hebron, Barcelona, Spain, [de Fabregues, O.] Hosp Univ Vall Hebron, Barcelona, Spain, [Cabo, I.] Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain, [Seijo, M.] Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain, [Lopez Manzanares, L.] Hosp Univ La Princesa, Madrid, Spain, [Gonzalez Aramburu, I.] Hosp Univ Marques Valdecilla, Santander, Spain, [Avila Rivera, M. A.] Hosp Gen Hosp, Consorci Sanitari Integral, Barcelona, Spain, [Catalan, M. J.] Hosp Univ Clin San Carlos, Madrid, Spain, [Nogueira, V.] Hosp Da Costa, Lugo, Spain, [Puente, V.] Hosp del Mar, Barcelona, Spain, [Garcia Moreno, J. M.] Hosp Univ Virgen Macarena, Seville, Spain, [Borrue, C.] Hosp Infanta Sofia, Madrid, Spain, [Solano Vila, B.] Inst Catala Salut, Inst Assistencia Sanitaria IAS, Girona, Spain, [Alvarez Sauco, M.] Hosp Gen Univ Elche, Elche, Spain, [Vela, L.] Fdn Hosp Alcorcon, Madrid, Spain, [Escalante, S.] Hosp Tortosa Verge Cinta IITVC, Tarragona, Spain, [Cubo, E.] Complejo Asistencial Univ Burgos, Burgos, Spain, [Carrillo Padilla, F.] Hosp Univ Canarias, San Cristobal De Laguna, Santa Cruz De T, Spain, [Martinez Castrillo, J. C.] Hosp Univ Ramon y Cajal, Madrid, Spain, [Sanchez Alonso, P.] Hosp Univ Puerta Hierro, Madrid, Spain, [Alonso Losada, M. G.] Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain, [Lopez Ariztegui, N.] Complejo Hosp Toledo, Toledo, Spain, [Gaston, I.] Complejo Hosp Navarra, Pamplona, Spain, [Kulisevsky, J.] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Blazquez Estrada, M.] Hosp Univ Cent Asturias, Oviedo, Spain, [Ruiz Martinez, J.] Hosp Univ Donostia, San Sebastian, Spain, [Valero, C.] Hosp Arnau Vilanova, Valencia, Spain, [Kurtis, M.] Hosp Ruber Int, Madrid, Spain, [Gonzalez Ardura, J.] Hosp Univ Lucus Augusti HULA, Lugo, Spain, [Ordas, C.] Hosp Rey Juan Carlos, Madrid, Spain, [Lopez Diaz, L.] Complejo Hosp Univ Orense CHUO, Orense, Spain, and [COPPADIS Study Grp] Fdn Curemos Parkinson, C Juana Vega 23 2, La Coruna 15004, Spain
- Subjects
medicine.medical_specialty ,Discapacitats ,Parkinson's disease ,Article Subject ,Degenerative Disorder ,Parkinson, Malaltia de - Prognosi ,Neuroscience (miscellaneous) ,Disease ,Stage ii ,personas::personas con discapacidad [DENOMINACIONES DE GRUPOS] ,Parkinson’s Disease ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades de los ganglios basales::trastornos parkinsonianos::enfermedad de Parkinson [ENFERMEDADES] ,Malaltia de Parkinson ,Internal medicine ,medicine ,Motor and nonmotor symptoms (NMS) ,Stage (cooking) ,RC346-429 ,030304 developmental biology ,ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD] ,Subtypes ,0303 health sciences ,Questionnaire ,business.industry ,Neurodegenerative disorder ,medicine.disease ,humanities ,Scale ,Psychiatry and Mental health ,Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE] ,Impact ,Persons::Disabled Persons [NAMED GROUPS] ,Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease [DISEASES] ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,Stage iv ,business ,030217 neurology & neurosurgery ,Qualitat de vida - Avaluació ,Research Article - Abstract
COPPADIS Study Group., [Introduction] In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient’s quality of life (QoL) with regard to a defined clinical stage., [Materials and Methods] Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0–20; B: NMSS = 21–40; C: NMSS = 41–70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale., [Results] A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (; e.g., PDQ-39SI in 1D [n = 15] vs 2A [n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; )., [Conclusion] The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.
- Published
- 2021
3. Mood in Parkinson's disease: From early- to late-stage disease.
- Author
-
Santos‐García, Diego, De Deus, Fonticoba T., Cores, Bartolome C., Valdés, Aymerich L., Suárez, Castro E., Aneiros, Ángel, Jesús, Silvia, Aguilar, Miquel, Pastor, Pau, Planellas, Lluís, Cosgaya, Marina, García, Caldente J., Caballol, Nuria, Legarda, Inés, Hernández, Vara J., Cabo, Iria, López, Manzanares L., González, Aramburu I., Ávila, Rivera M. A., and José, Catalán M.
- Subjects
PARKINSON'S disease ,QUALITY of life ,IMPULSE control disorders - Abstract
Background: Although depression is known to be frequent in Parkinson's disease (PD), it is unclear how mood can change and/or impact on patient's quality of life (QoL) over time. Our aim was to analyze the frequency of depression, mood related factors and the contribution of mood to a patient's QoL perception in regard to disease duration.Methods: PD patients recruited from the COPPADIS cohort from January 2016 to November 2017 were included in this cross-sectional study. Three groups were defined: <5 years (Group A); from 5 to <10 years (Group B); ≥10 years (Group C). Analysis with well-planned linear regression models was conducted to determine how different factors contribute to mood (Beck Depression Inventory-II [BDI-II] as dependent variable), to health-related QoL (39-item Parkinson's Disease Questionnaire [PDQ-39SI] as dependent variable) and to global QoL (European Health Interview Survey - Quality of Life Eight-Item Index [EUROHIS-QOL8] as dependent variable).Results: Six hundred and sixty-three PD patients (62.6 ± 8.9 years old, 59.6% males) were included: Group A, 50.1% (n = 332); Group B, 33.3% (n = 221) and Group C, 16.6% (n = 110). There were no differences between the three groups in terms of the frequency of depressive symptoms nor the frequency of depression type (major vs. minor vs. subthreshold) (p = 0.729). However, the unique percent variance of PDQ-39SI and EUROHIS-QOL8 explained by BDI-II total score was 2 (23.7%) and threefold (26.9%), respectively, in Group C compared to the other two groups. EUROHIS-QOL8 total score provided the highest unique contribution to mood (16.8%).Conclusions: Although depression-type frequency does not appear to change over time in PD; the contribution of mood on QoL perception is greater in patients with longer disease duration. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation.
- Author
-
Santos García, D., Jesús, S., Aguilar, M., Planellas, L. L., García Caldentey, J., Caballol, N., Legarda, I., Hernández Vara, J., Cabo, I., López Manzanares, L., González Aramburu, I., Ávila Rivera, M. A., Catalán, M. J., López Díaz, L., Puente, V., García Moreno, J. M., Borrué, C., Solano Vila, B., Álvarez Sauco, M., and Vela, L.
- Subjects
PARKINSON'S disease ,DISEASE progression ,IMPULSE control disorders ,MENTAL depression ,DISEASE duration - Abstract
Background and purpose: In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well‐designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS‐2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). Methods: This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. Results: In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non‐Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non‐motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Conclusions: Parkinson's disease is a complex disorder and different non‐motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON™.
- Author
-
Santos García D, López Ariztegui N, Cubo E, Vinagre Aragón A, García-Ramos R, Borrué C, Fernández-Pajarín G, Caballol N, Cabo I, Barrios-López JM, Hernández Vara J, Ávila Rivera MA, Gasca-Salas C, Escalante S, Manrique de Lara P, Pérez Noguera R, Álvarez Sauco M, Sierra M, Monje MHG, Sánchez Ferro A, Novo Ponte S, Alonso-Frech F, Macías-García D, Legarda I, Rojo A, Álvarez Fernández I, Buongiorno MT, Pastor P, and García Ruíz P
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Surveys and Questionnaires, Neurologists, Parkinson Disease, Gait Disorders, Neurologic
- Abstract
Background: STAT-ON™ is an objective tool that registers ON-OFF fluctuations making possible to know the state of the patient at every moment of the day in normal life. Our aim was to analyze the opinion of different Parkinson's disease experts about the STAT-ON™ tool after using the device in a real clinical practice setting (RCPS)., Methods: STAT-ON™ was provided by the Company Sense4Care to Spanish neurologists for using it in a RCPS. Each neurologist had the device for at least three months and could use it in PD patients at his/her own discretion. In February 2020, a survey with 30 questions was sent to all participants., Results: Two thirds of neurologists (53.8% females; mean age 44.9±9 years old) worked in a Movement Disorders Unit, the average experience in PD was 16±6.9 years, and 40.7% of them had previously used other devices. A total of 119 evaluations were performed in 114 patients (range 2-9 by neurologist; mean 4.5±2.3). STAT-ON™ was considered "quite" to "very useful" by 74% of the neurologists with an overall opinion of 6.9±1.7 (0, worst; 10, best). STAT-ON™ was considered better than diaries by 70.3% of neurologists and a useful tool for the identification of patients with advanced PD by 81.5%. Proper identification of freezing of gait episodes and falls were frequent limitations reported., Conclusion: STAT-ON™ could be a useful device for using in PD patients in clinical practice., (Published by Elsevier España, S.L.U.)
- Published
- 2023
- Full Text
- View/download PDF
6. Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON™.
- Author
-
Santos García D, López Ariztegui N, Cubo E, Vinagre Aragón A, García-Ramos R, Borrué C, Fernández-Pajarín G, Caballol N, Cabo I, Barrios-López JM, Hernández Vara J, Ávila Rivera MA, Gasca-Salas C, Escalante S, Manrique de Lara P, Pérez Noguera R, Álvarez Sauco M, Sierra M, Monje MHG, Sánchez Ferro A, Novo Ponte S, Alonso-Frech F, Macías-García D, Legarda I, Rojo A, Álvarez Fernández I, Buongiorno MT, Pastor P, and García Ruíz P
- Abstract
Background: STAT-ON™ is an objective tool that registers ON-OFF fluctuations making possible to know the state of the patient at every moment of the day in normal life. Our aim was to analyze the opinion of different Parkinson's disease experts about the STAT-ON™ tool after using the device in a real clinical practice setting (RCPS)., Methods: STAT-ON™ was provided by the Company Sense4Care to Spanish neurologists for using it in a RCPS. Each neurologist had the device for at least three months and could use it in PD patients at his/her own discretion. In February 2020, a survey with 30 questions was sent to all participants., Results: Two thirds of neurologists (53.8% females; mean age 44.9±9 years old) worked in a Movement Disorders Unit, the average experience in PD was 16±6.9 years, and 40.7% of them had previously used other devices. A total of 119 evaluations were performed in 114 patients (range 2-9 by neurologist; mean 4.5±2.3). STAT-ON™ was considered "quite" to "very useful" by 74% of the neurologists with an overall opinion of 6.9±1.7 (0, worst; 10, best). STAT-ON™ was considered better than diaries by 70.3% of neurologists and a useful tool for the identification of patients with advanced PD by 81.5%. Proper identification of freezing of gait episodes and falls were frequent limitations reported., Conclusion: STAT-ON™ could be a useful device for using in PD patients in clinical practice., (Copyright © 2020 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression.
- Author
-
Santos-García D, de Deus Fonticoba T, Suárez Castro E, Aneiros Díaz A, Cores Bartolomé C, Feal Panceiras MJ, Paz González JM, Valdés Aymerich L, García Moreno JM, Blázquez Estrada M, Jesús S, Mir P, Aguilar M, Planellas LL, García Caldentey J, Caballol N, Legarda I, Cabo López I, López Manzanares L, Ávila Rivera MA, Catalán MJ, López Díaz LM, Borrué C, Álvarez Sauco M, Vela L, Cubo E, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Pascual-Sedano B, Seijo M, Ruíz Martínez J, Valero C, Kurtis M, González Ardura J, Prieto Jurczynska C, and Martinez-Martin P
- Subjects
- Depression epidemiology, Depression etiology, Fatigue epidemiology, Fatigue etiology, Humans, Surveys and Questionnaires, Parkinson Disease complications, Parkinson Disease epidemiology, Quality of Life
- Abstract
Background: The role of subthreshold depression (subD) in Parkinson's Disease (PD) is not clear. The present study aimed to compare the quality of life (QoL) in PD patients with subD vs patients with no depressive disorder (nonD). Factors related to subD were identified., Material and Methods: PD patients and controls recruited from the COPPADIS cohort were included. SubD was defined as Judd criteria. The 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8) were used to assess QoL., Results: The frequency of depressive symptoms was higher in PD patients (n = 694) than in controls (n = 207) (p < 0.0001): major depression, 16.1% vs 7.8%; minor depression, 16.7% vs 7.3%; subD, 17.4% vs 5.8%. Both health-related QoL (PDQ-39; 18.1 ± 12.8 vs 11.6 ± 10; p < 0.0001) and global QoL (EUROHIS-QOL8; 3.7 ± 0.5 vs 4 ± 0.5; p < 0.0001) were significantly worse in subD (n = 120) than nonD (n = 348) PD patients. Non-motor Symptoms Scale (NMSS) total score was higher in subD patients (45.9 ± 32 vs 29.1 ± 25.8;p < 0.0001). Non-motor symptoms burden (NMSS;OR = 1.019;95%CI 1.011-1.028; p < 0.0001), neuropsychiatric symptoms (NPI; OR = 1.091; 95%CI 1.045-1.139; p < 0.0001), impulse control behaviors (QUIP-RS; OR = 1.035; 95%CI 1.007-1063; p = 0.013), quality of sleep (PDSS; OR = 0.991; 95%CI 0.983-0.999; p = 0.042), and fatigue (VAFS-physical; OR = 1.185; 95%CI 1.086-1.293; p < 0.0001; VAFS-mental; OR = 1.164; 95%CI 1.058-1.280; p = 0.0001) were related to subD after adjustment to age, disease duration, daily equivalent levodopa dose, motor status (UPDRS-III), and living alone., Conclusions: SubD is a frequent problem in patients with PD and is more prevalent in these patients than in controls. QoL is worse and non-motor symptoms burden is greater in subD PD patients., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
8. Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease.
- Author
-
Santos-García D, de Deus Fonticoba T, Suárez Castro E, Aneiros Díaz A, McAfee D, Catalán MJ, Alonso-Frech F, Villanueva C, Jesús S, Mir P, Aguilar M, Pastor P, García Caldentey J, Esltelrich Peyret E, Planellas LL, Martí MJ, Caballol N, Hernández Vara J, Martí Andrés G, Cabo I, Ávila Rivera MA, López Manzanares L, Redondo N, Martinez-Martin P, and McAfee D
- Subjects
- Aged, Cross-Sectional Studies, Female, Humans, Levodopa therapeutic use, Male, Middle Aged, Severity of Illness Index, Parkinson Disease complications, Parkinson Disease epidemiology
- Abstract
Background and Purpose: The objective of this study was to analyze the relationship between motor complications and non-motor symptom (NMS) burden in a population of patients with Parkinson's disease (PD) and also in a subgroup of patients with early PD., Methods: Patients with PD from the COPPADIS cohort were included in this cross-sectional study. NMS burden was defined according to the Non-Motor Symptoms Scale (NMSS) total score. Unified Parkinson's Disease Rating Scale (UPDRS) part IV was used to establish motor complication types and their severity. Patients with ≤5 years of symptoms from onset were included as patients with early PD., Results: Of 690 patients with PD (62.6 ± 8.9 years old, 60.1% males), 33.9% and 18.1% presented motor fluctuations and dyskinesia, respectively. The NMS total score was higher in patients with motor fluctuations (59.2 ± 43.1 vs. 38.3 ± 33.1; P < 0.0001) and dyskinesia (63.5 ± 40.7 vs. 41.4 ± 36.3; P < 0.0001). In a multiple linear regression model and after adjustment for age, sex, disease duration, Hoehn & Yahr stage, UPDRS-III score and levodopa equivalent daily dose, UPDRS-IV score was significantly related to a higher NMSS total score (β = 0.27; 95% confidence intervals, 2.81-5.61; P < 0.0001), as it was in a logistic regression model on dichotomous NMSS total score (≤40, mild or moderate vs. >40, severe or very severe) (odds ratio, 1.31; 95% confidence intervals, 1.17-1.47; P < 0.0001). In the subgroup of patients with early PD (n = 396; mean disease duration 2.7 ± 1.5 years), motor fluctuations were frequent (18.1%) and similar results were obtained., Conclusions: Motor complications were frequent and were associated with a greater NMS burden in patients with PD even during the first 5 years of disease duration., (© 2020 European Academy of Neurology.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.